Article Details

RedHill Biopharma says its Phase 2/3 COVID-19 drug candidate opaganib reduces thrombosis in ...

Retrieved on: 2020-12-16 14:29:04

Tags for this article:

Click the tags to see associated articles and topics

RedHill Biopharma says its Phase 2/3 COVID-19 drug candidate opaganib reduces thrombosis in .... View article details on hiswai:

Excerpt

RedHill <b>Biopharma</b> Ltd (NASDAQ:RDHL) (FRA:2RH) revealed promising preliminary results on Tuesday from a preclinical study on its advanced ...

Article found on: www.proactiveinvestors.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up